⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PSTV News
PLUS THERAPEUTICS, Inc. Common Stock
Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants
globenewswire.com
PSTV
Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
globenewswire.com
PSTV
Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium
globenewswire.com
PSTV
Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases
globenewswire.com
PSTV
Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
globenewswire.com
PSTV
HUM
Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement
globenewswire.com
PSTV
Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0
globenewswire.com
PSTV
Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights
globenewswire.com
PSTV
Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge
prnewswire.com
GTBP
GDTC
PSTV
IOVA
IMAB
GTBP
GDTC
PSTV
IOVA
IMAB
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
globenewswire.com
PSTV